| Symbol | ALZN |
|---|---|
| Name | ALZAMEND NEURO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3480 PEACHTREE ROAD NE,SECOND FLOOR SUITE 103, ATLANTA, Georgia, 30326, United States |
| Telephone | +1 844 722-6303 |
| Fax | — |
| — | |
| Website | https://www.alzamend.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001677077 |
| Description | Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimers. Its mission is to develop and market safe and effective treatments. The companys pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patients immunological system to combat Alzheimers. Additional info from NASDAQ: |
New Form PRE 14A - Alzamend Neuro, Inc. <b>Filed:</b> 2026-08-28 <b>AccNo:</b> 0001214659-26-011083 <b>Size:</b> 747 KB
Read moreNew Form S-1 - Alzamend Neuro, Inc. <b>Filed:</b> 2026-08-21 <b>AccNo:</b> 0001214659-26-010726 <b>Size:</b> 440 KB
Read moreNew Form 4/A - Alzamend Neuro, Inc. <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001214659-26-010677 <b>Size:</b> 16 KB
Read moreNew Form 3/A - Alzamend Neuro, Inc. <b>Filed:</b> 2026-08-20 <b>AccNo:</b> 0001214659-26-010676 <b>Size:</b> 12 KB
Read moreAlzamend Neuros Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Read moreAlzamend Neuros Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Read moreAlzamend Neuros Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Read moreAlzamend Neuros Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Read moreAlzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Read moreAlzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07540338 | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an A… | Phase1 | Bipolar I Disorder | Recruiting | 2026-05-11 | 2026-12-01 | ClinicalTrials.gov |
| NCT06921590 | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an A… | Phase1 | Pharmacokinetics | Completed | 2025-05-09 | 2025-12-15 | ClinicalTrials.gov |
| NCT05834296 | Study in Subjects With Mild-to-Moderate Alzheimer's Dementia | Phase1 | Alzheimer Disease | Active_Not_Recruiting | 2023-07-05 | 2028-03-03 | ClinicalTrials.gov |
| NCT05363293 | Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's … | Phase1 | Alzheimer's Disease | Completed | 2022-05-04 | 2023-05-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Lithium Carbonate Capsule | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT06921590 |
| AL001 | Other | Phase PHASE1 | Pharmacokinetics | COMPLETED | NCT06921590 |
| Lithium carbonate | Other | Phase PHASE1 | Bipolar I Disorder | RECRUITING | NCT07540338 |
| AL001 | Other | Phase PHASE1 | Bipolar I Disorder | RECRUITING | NCT07540338 |
| Placebo | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT05363293 |
| AL001 | Other | Phase PHASE1 | Alzheimer's Disease | COMPLETED | NCT05363293 |
| Placebo | Other | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05834296 |
| ALZN002 (autologous DCs pulsed with E22W mutant peptide). | Other | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05834296 |
| Lithium Carbonate Capsule | Other | Phase PHASE1 | Pharmacokinetics | ACTIVE_NOT_RECRUITING | NCT06921590 |
| AL001 | Other | Phase PHASE1 | Pharmacokinetics | ACTIVE_NOT_RECRUITING | NCT06921590 |
| Lithium carbonate | Other | Phase PHASE1 | Bipolar I Disorder | RECRUITING | NCT07540338 |
| AL001 | Other | Phase PHASE1 | Bipolar I Disorder | RECRUITING | NCT07540338 |
| Lithium Carbonate Capsule | DRUG | Phase PHASE1 | Pharmacokinetics | ACTIVE_NOT_RECRUITING | NCT06921590 |
| ALZN002 (autologous DCs pulsed with E22W mutant peptide). | BIOLOGICAL | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05834296 |
| Placebo | DRUG | Phase PHASE1 | Alzheimer Disease | ACTIVE_NOT_RECRUITING | NCT05834296 |
| AL001 | DRUG | Phase PHASE1 | Pharmacokinetics | ACTIVE_NOT_RECRUITING | NCT06921590 |